Aims & Scope
Current Cancer Drug Targets aims to cover all the latest and outstanding developments in full spectrum of cancer drug discovery and development, including but not limited to cellular and molecular biology, genomics, proteomics, metabolomics, medicinal chemistry, pharmacology, toxicology, and biochemistry of contemporary molecular drug targets involved in cancer, e.g. disease specific proteins, receptors, enzymes and genes.
Current Cancer Drug Targets publishes original research articles, letters/commentary/perspectives, reviews / mini-reviews, drug clinical trial studies and guest edited thematic issues written by leaders in the field covering a range of current topics on drug targets involved in cancer.
As the discovery, identification, characterization and validation of novel drug targets for human anticancer drug discovery continues to grow, this journal has become essential reading for all biomedical and pharmaceutical scientists involved in drug discovery and development. Its scope covers publications related to prevention, diagnosis and treatment of all types of human cancers in various of basic and translational researches, including cancer etiology, signal transduction, biomarker, chemotherapy, hormone therapy, gene therapy, immunotherapy, radiotherapy, immunotherapy and combination therapy, stem cell, tumor environment, metabolism emphasizing on advanced mechanistic investigations.
BIOBASE, Biochemistry & Biophysics Citation Index®, BIOSIS, BIOSIS Previews, BIOSIS Reviews Reports and Meetings, Biotechnology Citation Index®, British Library, Cambridge Scientific Abstracts (CSA)/ProQuest, Chemical Abstracts Service/SciFinder, ChemWeb, CNKI Scholar, Dimensions, EBSCO, EMBASE, ERA 2018, Genamics JournalSeek, Google Scholar, InCites, Index Copernicus, Index to Scientific Reviews®, ISI Alerting Service, J-Gate, Journal Citation Reports/Science Edition, JournalTOCs, MediaFinder®-Standard Periodical Directory, MEDLINE/PubMed/Index Medicus, Open Abstracts (I4OA), Norwegian Register, Prous Science Integrity, PubsHub, QOAM, Science Citation Index Expanded™ (SciSearch®), Scilit, Scopus, Suweco CZ, TOC Premier, and Ulrich's Periodicals Directory
Current Cancer Drug Targets was launched in 2001. Dr. Ruiwen Zhang serves as the Editor-in-Chief of the journal.
"In view of the growing volume of literature, the role of high quality review journals has become increasingly important. Current Drug Targets is an important journal in the field of medicinal chemistry and drug design, which is strongly recommended to the scientific community."
It was a nice experience to publish our article in current drug target. I felt that the journal is quick and has maintained very high standard by independently reviewing article from more than five reviewers. The communication between the author and the Journals editorial is also speedy. I hope the journal will continue to maintain and sustain its reputation.
Pushpender K. Sharma
(Department of Biotechnology, Sri Guru Granth Sahib World University, Fatehgarh Sahib, Pb, India.)